Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Lifecare reduces operating loss in Q2 2026 and secures financing until Q2 2027
Lifecare reports an operating loss of NOK 10.6m for Q2 2026 versus NOK 22m in the prior year and improved liquidity of NOK 37m. Revenue remained minimal at NOK 250,000, coming from a government grant; net profit of NOK 4.5m resulted from revaluations and the deconsolidation of the German subsidiary. Management plans to relocate and build a controlled production facility in Bergen as a prerequisite for the CE submission; financial runway is expected to last until Q2 2027, but a CE timeline in 2027 remains uncertain. » More on de.investing.com
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 34.67k | 24.30% |
| Gross profit | 0 | - |
| Net profit | -1.12m | 79.67% |
| EBITDA | -1.06m | 80.28% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €14.24m |
Number of shares | 430.36m |
52-week high/low | €0.55 - €0.0255 |
| Dividends | No |
Beta | -0.43 |
P/E ratio | -0.55 |
PEG ratio | 0.00 |
P/B ratio | 2.89 |
P/S ratio | 99.43 |
Company profile
Lifecare AS engages in the research and development of medical sensors for health monitoring in Norway. It develops Sencell, a micro sensor for monitoring glucose levels in patients with diabetes. The company was founded in 2006 and is headquartered in Bergen, Norway.
| Name | LIFECARE AS NOK 0,40 |
| CEO | Joacim Holter |
| Headquarters | Bergen,
hl Norway |
| Website | |
| IPO | 11/07/2018 |
| Employees | 22 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Osl | LIFE.OL |
Frankfurt | LFC.F |
Düsseldorf | LFC.DU |
München | LFC.MU |